Medical Meetings

Our success as a next-generation BioPharma company will be measured by the difference we can make in the lives of patients facing serious disease. Members of the press may learn more about our company, our philanthropy and our focus on innovative medicines by viewing these resources.

BMS at ASCO and EHA 2022

At this year’s ASCO and EHA meetings, we shared research across immuno-oncology, hematology and cell therapy that underscores our efforts in delivering long-term survival and improved outcomes for patients.

BMS at ACTRIMS Forum 2022 >

At the ACTRIMS Forum 2022, Bristol Myers Squibb presented new research findings, with the goal of preserving physical and cognitive functions in people living with MS.

BMS at ECCO 2022 >

At the European Crohn’s and Colitis Organization (ECCO) 2022 Congress, Bristol Myers Squibb shared the latest research and breakthroughs for patients with gastrointestinal (GI) immune-mediated diseases.

BMS at AHA Scientific Sessions 2021 >

At the AHA 2021 Scientific Sessions, Bristol Myers Squibb shared updates from our robust cardiovascular pipeline and highlighted key research programs that propel discovery of treatment options for patients with cardiovascular disease.

BMS at the 63rd ASH Annual Meeting & Exposition >

At the American Society of Hematology (ASH) Annual Meeting 2021, Bristol Myers Squibb shared new data demonstrating the strength of our our innovative therapeutic platforms and modalities in a broad range of hematologic diseases.